SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-019856
Filing Date
2023-05-09
Accepted
2023-05-09 17:19:03
Documents
15
Period of Report
2023-05-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K janx-20230509.htm   iXBRL 8-K 69677
2 EX-1.1 janx-ex1_1.htm EX-1 422764
3 EX-5.1 janx-ex5_1.htm EX-5 35498
4 GRAPHIC img151594875_0.jpg GRAPHIC 29364
  Complete submission text file 0000950170-23-019856.txt   771921

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20230509_pre.xml EX-101.PRE 12070
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20230509.xsd EX-101.SCH 2471
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20230509_lab.xml EX-101.LAB 19440
9 EXTRACTED XBRL INSTANCE DOCUMENT janx-20230509_htm.xml XML 5113
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 23903431
SIC: 2834 Pharmaceutical Preparations